ライフサイエンスコーパス: human serum

1 so checked to detect QA in the real samples (human serum).

2 y target of neutralizing activity present in human serum.

3 ed with the increase of CEA concentration in human serum.

4 evels of SRM 972a are composed of unmodified human serum.

5 lly extended to the detection of the drug in human serum.

6 ce was successfully applied to detect AFP in human serum.

7 that THP is primarily in a monomeric form in human serum.

8 detection of glucose in artificial urine and human serum.

9 resistant to killing by complement in normal human serum.

10 of miRNA targets in 20microl of unprocessed human serum.

11 liced form FH-like protein 1 when exposed to human serum.

12 racted from several mammalian cell lines and human serum.

13 to detect disease-specific miRNA targets in human serum.

14 age degradation, followed by incubation with human serum.

15 yolk and phospholipids/phosphopeptides from human serum.

16 nsor was effectively applied to detect Mb in human serum.

17 duced and three 5beta-reduced metabolites in human serum.

18 ctrometry to quantify 493 small molecules in human serum.

19 rement for the determination of serotonin in human serum.

20 HILIC enriched glycopeptides extracted from human serum.

21 tide alone, and showed enhanced stability in human serum.

22 all product ions, was applied to a sample of human serum.

23 he naked eye in buffer samples and undiluted human serum.

24 more resistant to in vitro metabolization in human serum.

25 to quantify glucose in honey, white wine and human serum.

26 same model assay after spiking anti-IgG into human serum.

27 demonstrate reduced resistance to killing by human serum.

28 ith macrophage colony-stimulating factor and human serum.

29 holesterol, when tested on complex system of human serum.

30 -expressing Escherichia coli when exposed to human serum.

31 subsequently challenged with heat, time, and human serum.

32 nt portions of samples from the same pool of human serum.

33 of the LIS device for detecting L-Alanine in human serum.

34 uit C1-INH to their surfaces when exposed to human serum.

35 selectivity that allowed us to detect LYS in human serum.

36 irectly measuring biological samples such as human serum.

37 abilized against degradation by nucleases in human serum.

38 more sensitive to beta-lactam antibiotics in human serum.

39 e mouse serum samples and a curated panel of human serum.

40 fHbp and promotes survival of N. cinerea in human serum.

41 ted by measuring Zika antigen in a simulated human serum.

42 lpha9alpha10 nAChR and improved stability in human serum.

43 ed enrichment of N-linked glycopeptides from human serum.

44 trated using the artificial matrix mimicking human serum.

45 say was processed in bovine serum albumin or human serum.

46 that mediates cell binding and resistance to human serum.

47 Following incubation in human serum, [(18)F]-9 indicates presence of parental co

48 thmic BoNT/A concentrations in PBS, milk and human serum across a 0.27-268pgmL(-1) range and associat

49 cropa-Tmab retained >99 % of its (225) Ac in human serum after 7 days.

50 toxicants and toxic electrophiles react with human serum albumin (albumin); however, the chemistry of

51 ied DNA aptamers specifically bound glycated human serum albumin (GHSA), which is an intermediate mar

52 nted with 10% dimethyl sulfoxide (DMSO), 15% human serum albumin (HSA) and 0.1% hyaluronans.

53 umina rugate filters (NAA-RFs) modified with human serum albumin (HSA) and reflectometric interferenc

54 sing testosterone and its transport proteins human serum albumin (HSA) and sex hormone binding globul

55 hierarchical structure for determination of human serum albumin (HSA) are designed and fabricated.

56 and highly disulfide-bonded proteins such as human serum albumin (HSA) by online EC reduction of nonr

57 Glycation of human serum albumin (HSA) can also be measured using thi

58 ting molecularly imprinted polymer (MIP) for human serum albumin (HSA) determination using semi-coval

59 he kinetics and affinities of fibrinogen and human serum albumin (HSA) for TiO2, CeO2, Al2O3 and ZnO

60 to human A2, C1, and C2 domains presented as human serum albumin (HSA) fusion proteins.

61 umins such as bovine serum albumin (BSA) and human serum albumin (HSA) have found a wide range of bio

62 s, we profiled adducts at the Cys34 locus of human serum albumin (HSA) in 29 nonsmoking Xuanwei and F

63 The label-free detection of human serum albumin (HSA) in aqueous buffer is demonstra

64 Human serum albumin (HSA) is a natural carrier protein p

65 pten was detected on four lysine residues of human serum albumin (HSA) isolated from tolerant patient

66 finity for PSMA and appropriate affinity for human serum albumin (HSA) may demonstrate a higher thera

67 ions, we loaded ATO onto folate (FA)-labeled human serum albumin (HSA) pretreated with glutathione (G

68 mustard (SM) produces a covalent adduct with human serum albumin (HSA) representing an established pl

69 Trypsin-digested, SDA-cross-linked human serum albumin (HSA) served as a test sample, yield

70 Human serum albumin (HSA) serves not only as a physiolog

71 -density-lipoprotein (VLDL) yields 1-3%, and human serum albumin (HSA) yields 0-2%.

72 article starts with a brief introduction of human serum albumin (HSA), and then summarizes the mains

73 Three albumins have been considered, namely human serum albumin (HSA), fatty acid free HSA (ffHSA) a

74 ein (human Kallikrein 2) and low response to human serum albumin (HSA), suggesting possible resilienc

75 enous inhibitor of Abeta self-association is human serum albumin (HSA), which binds approximately 90%

76 es CTX, bovine thyroglobulin (Bos d TG), and human serum albumin (HSA)-conjugated alpha-Gal.

77 A structures with strong binding affinity to human serum albumin (HSA).

78 to describe the interaction between 2PHE and human serum albumin (HSA).

79 antages of unusually long serum half-life of human serum albumin (HSA).

80 t 50 mM(-1) s(-1) upon binding to Zn(II) and human serum albumin (HSA).

81 librium dissociation constant for Zn(2+) and human serum albumin (Kd = (5.62 +/- 0.93) x 10(-7) M) un

82 strong and specific affinity of recombinant human serum albumin (rHSA) towards cholesteryl-modified

83 egated serum albumin [MAA]) and (99m)Tc-HSA (human serum albumin [HSA]), was assessed.

84 The contents of two amide-AGEs in human serum albumin and apolipoprotein A-II were signifi

85 n mice passively sensitized to dinitrophenol-human serum albumin and challenged intradermally.

86 fect outcomes, administration of ultra-clean human serum albumin at protein concentrations equivalent

87 Human serum albumin binding assays indicated that the re

88 binding affinity between drug molecules and human serum albumin by combining nanoporous anodic alumi

89 ides because of the high binding affinity of human serum albumin for fatty acids.

90 Conjugation of fatty acid, a natural human serum albumin ligand, to a therapeutic protein/pep

91 Noncovalent binding of biopharmaceuticals to human serum albumin protects against enzymatic degradati

92 er, lapatinib release from a nanoshell-based human serum albumin protein host complex resulted in inc

93 wed higher solubilities and lower binding to human serum albumin than that of Mocetinostat.

94 xploit the intrinsic transport properties of human serum albumin to tune the blood circulatory half-l

95 Finally, human serum albumin was found to bind NO2-CLA both non-c

96 herefore, the interaction between KP1019 and human serum albumin was investigated by means of X-ray c

97 an antibody binding site, HSA Peptide 40, on human serum albumin with nanomolar affinity for all thre

98 ter inhibition with a CCD inhibitor (MUXF(3)-human serum albumin).

99 mer peptide, which lies in Subdomain IIIA of human serum albumin, blocks binding of all three antibod

100 the tryptic digests of three model proteins (Human Serum Albumin, creatine kinase, and myoglobin).

101 ds in lysozyme and all 17 disulfide bonds in human serum albumin, including nested disulfide bonds an

102 more than 95% of model biochemical species (human serum albumin, neurotensin, creatinine, glycine, a

103 oci of blood proteins, particularly Cys34 of human serum albumin, which is the dominant scavenger of

104 aRIIIA-specific antibody linked in tandem to human serum albumin, which retained FcgammaR-binding act

105 rawn and replaced with an equal volume of 5% human serum albumin-saline mixture) to reduce [Hb] (Low

106 teinylglycine, and beta-mercaptoethanol) and human serum albumin.

107 albumin, beta-lactoglobulin, soy protein and human serum albumin.

108 no binding between the peptide oligomers and human serum albumin.

109 xchange chromatography based purification of human serum albumin.

110 Direct deployment in human serum allowed sensitive detection of different NS1

111 in (TTR), avidin, concanavalin A (conA), and human serum amyloid P component (SAP) at elevated temper

112 r, the resulting device was proven useful in human serum analysis, achieving a LOD of 6.30ngmL(-1) in

113 clinically relevant range, using unprocessed human serum and a disposable microfluidic device; no opt

114 n the presence of simulated body fluids SBF, human serum and blood enriched with ethanol as fuels.

115 nation of potassium and lithium in undiluted human serum and blood with attractive precision.

116 omegalovirus (HCMV) were readily detected in human serum and can interfere with lymphocyte responses

117 CL5 in clinically relevant concentrations in human serum and colorectal cancer cells samples with hig

118 ssessed by successful analysis of the IgE in human serum and comparison of results with those from a

119 the O-antigen mediated enhanced survival in human serum and decreased complement binding.

120 nd specificity assays were carried out using human serum and different proteins.

121 vitro, occur in vivo, we analyzed samples of human serum and epidermis, and pig adrenals for the pres

122 terol and 17,20-dihydroxypregnalumisterol in human serum and epidermis, and the porcine adrenal gland

123 asensor was also used to analyze AFB1 spiked human serum and grape juice samples and the recoveries w

124 nogen concentrations (938-44,542mug/dL) from human serum and human whole blood samples using this bio

125 Human serum and IGNIS prime peptides were digested and t

126 m formation in vitro in the presence of 100% human serum and metabolism of beta-methyl-D-glucoside.

127 ons of (225)Ac(3+) ions: one rapidly lost in human serum and one that remains bound to the US-tubes d

128 applied in captopril determination in spiked human serum and pharmaceutical dosage forms with accepta

129 iron oxide core-shell nanoworms incubated in human serum and plasma are rapidly opsonized with the th

130 odies against Treponema pallidum antigens in human serum and plasma.

131 luid phase and such complexes are present in human serum and plasma.

132 the immunosensor is used to PSA detection in human serum and prostate tissue samples and the obtained

133 s 20 copies of Ebola virus templates in both human serum and saliva and could be adapted to distingui

134 e and fast detection of TNF alpha antigen in human serum and satisfied recoveries (98.69-105.20%) wer

135 A-deficient mutant was efficiently killed by human serum and showed a defect in the penetration of en

136 Application of DD-SRM to human serum and tissue provides precise quantification o

137 iRNAs in a variety of sample types including human serum and total RNA.

138 compounds and metabolites, were analyzed in human serum and urine samples from the general populatio

139 onstrated by the analysis of the alkaloid in human serum and urine samples.

140 challenged with either excess La(3+) ions or human serum, and did not accumulate in any organ after 5

141 on of the peptide is biochemically stable in human serum, and most serum-stable fragments have full a

142 lycoprotein suspended in diluted PBS buffer, human serum, and plasma.

143 egative-ion mode to phospholipids present in human serum, and the data set was used to evaluate the v

144 However, studies of SR BrN antibodies in human serum, and their association with natural infectio

145 Immunoglobulin G1 (IgG1), a subclass of human serum antibodies, is the most widely used scaffold

146 l (SRM) 972a Vitamin D Metabolites in Frozen Human Serum as a replacement for SRM 972, which is no lo

147 Experiments using human serum as a source of complement proteins confirmed

148 two most common methods, in which AlbuMAX or human serum as additives are used, and the results were

149 s suggest that alterations of BDNF levels in human serum as reported in studies dealing with depressi

150 lied for chloride determination in undiluted human serum as well as artificial serum sample, the slop

151 We were able to detect BPA spiked in human serum as well as in maternal and cord blood within

152 g interferon-gamma (KD of 33 pM) survived in human serum at 37 degrees C after 3 days under our exper

153 or quantitative detection of CRP spiked into human serum at concentrations as low as 0.2 ng/mL, which

154 ible to perform single-molecule screening in human serum at ultra-low protein concentrations.

155 Both human serum based quality control (QC) and patient sampl

156 he present study, we found that properdin in human serum bound dose-dependently to solid-phase myelop

157 A simple post-adsorption of human serum:bovine serum albumin (HS:BSA) mixtures onto

158 and, Lipid 654 (L654), is present in healthy human serum but significantly decreased in the serum of

159 orrelates with survival of M. catarrhalis in human serum by inhibiting bactericidal activity of the c

160 e art for the determination of creatinine in human serum by isotope dilution mass spectrometry (IDMS)

161 r PCB congeners (</=0.20 wt % in Aroclor) in human serum collected from urban and rural adolescents a

162 odies was enhanced in the presence of intact human serum complement or purified C3a or C5a.

163 class I antibodies in the presence of intact human serum complement.

164 Compared with cultivation with human serum, cultivation with AlbuMAX increased the expr

165 Experiments using human serum depleted of specific complement components d

166 ilar FcRn binding kinetics to recombinant or human serum-derived HSA.

167 nted with inter-alpha-inhibitor (IalphaI), a human serum-derived protein, recently demonstrated to ac

168 uantitative detection of PSA in a buffer and human serum diluted 1/100.

169 Human serum diluted 1:2 with PBS buffer was analyzed by

170 protein, C-reactive protein (CRP), in normal human serum, displaying a calcium-dependent, high-avidit

171 1) IL-33 is difficult to detect by ELISA in human serum, due to lack of sensitivity and specificity

172 were less able to compete with FH in normal human serum during complement activation on mGEnCs, conf

173 The low abundance of bacterial proteins in human serum during infection imposes a challenge for ear

174 based on their relative peak area ratios in human serum during PRM assay development, with 4 protein

175 y peptide scavenging, but T2D pancreatic and human serum EVs have no effect.

176 As proof-of-concept, human serum exosomes were found to express SR-B1, and HD

177 Chromatography of rat brain, rat serum, and human serum extracts revealed two peaks of GPR139 activi

178 unctional consequences of the variability in human serum FH levels on host defense.

179 VEGF) and prostate-specific antigen (PSA) in human serum for early diagnosis of PCa.

180 nce liquid chromatography that was stable in human serum for more than 6 h and showed specific bindin

181 hibit picomolar to low nanomolar affinity in human serum for three diverse proteins, and show that th

182 eproducible approach to quantifying IL-33 in human serum from asthma patients.

183 Analysis of human serum from patients with AMD recapitulated these d

184 Indeed, direct exposure of PCCL3 cells to human serum from two patients with Graves' disease, but

185 erumoxytol was incubated in media containing human serum (group 1), fetal bovine serum (group 2), Ste

186 b was more than 95% stable after 24 hours in human serum, had an immunoreactivity of more than 70%, a

187 cTnT in phosphate buffered saline (PBS) and human serum (HS) buffers was achieved at low sample volu

188 erence from the parental strain in growth in human serum, human plasma, or sheep or horse blood.

189 ies, which were able to block the binding of human serum IgE.

190 S aureus extracellular proteins targeted by human serum IgG4 were identified by means of immunoblott

191 Human serum IgM Abs are composed of heavily glycosylated

192 MR measurements of calcium concentrations in human serum in the presence of magnesium.

193 The ability to directly sense proteins in human serum in this way overcomes the Debye length limit

194 ical solutions such as protein solutions and human serum, in order to improve the sensitivity of LIBS

195 mice when challenged with an infectious HCV human serum inoculum for a prolonged period.

196 pecificity of currently available assays; 2) human serum interferes with IL-33 quantification, in par

197 ly N-linked glycosite-containing peptides in human serum irrespective of disease state.

198 s between high- and low-toxicity isolates in human serum is a contributing factor.

199 selectively detect ICNKQDCPILE in a diluted human serum is also demonstrated.

200 ntify specific circulating autoantibodies in human serum is developed.

201 nalytical determination of both compounds in human serum is presented.

202 phins (Tursiops truncatus) and pooled normal human serum led to the discovery of 11 proteins that app

203 ly detected from a few hundred nanoliters of human serum loaded onto chromatography paper.

204 pid mediator profiling we identified MCTR in human serum, lymph nodes, and plasma and investigated MC

205 h those reported previously as a part of the Human Serum Metabolome Database.

206 to deplete hRSV-neutralizing antibodies from human serum more efficiently than Post-F-XC.

207 i strains are resistant to killing by normal human serum (NHS), an observation supported in this stud

208 t C3 was found to be an essential opsonin in human serum not only for greatly increased uptake of SCH

209 3D membranes has permitted the detection in human serum of as low as 25 pg/ml total prostate specifi

210 C3-inhibitor compstatin Cp40, in C3-depleted human serum, or when purified properdin is applied in bu

211 g disease-specific miRNA targets directly in human serum, our microarray platform has potential appli

212 tifying C-reactive protein concentrations in human serum over a large portion of the physiological ra

213 nzymatic linoleic acid peroxidation, inhibit human serum oxidation in the presence of copper ions and

214 , we reported on the mass analysis of intact human serum peptides and small proteins with isotopic re

215 human skin (in vitro) and harmonized in vivo human serum pharmacokinetic (PK) studies to evaluate the

216 ionization method using protein precipitated human serum, plasma and Surine (simulated urine) as stan

217 of the beta-blocker propranolol spiked into human serum, plasma, and urine at physiologically releva

218 pins and their PUFA precursors in 100 muL of human serum, plasma, urine, and cell culture supernatant

219 notating Cys34 adducts in tryptic digests of human serum/plasma.

220 Apolipoprotein L1 (ApoL1) is a human serum protein conferring resistance to African try

221 rnal factors, such as glucose, ascorbic acid human serum protein, immunoglobulin G, and immunoglobuli

222 l studies have emphasized the likely role of human serum proteins in the transportation and accumulat

223 ased from several glycoprotein standards and human serum proteins, we demonstrated that the Y1 ion tr

224 or karilysin, showed diminished survival in human serum, providing further evidence for the synergis

225 In human serum, PYY concentrations were higher in samples w

226 ial cells obtained with an Orbitrap and from human serum replicates generated on a quadrupole-time-of

227 f Zika NS1 to be carried out in 10% and 100% human serum, respectively.

228 Using a pooled human serum sample and a pooled mouse plasma sample as t

229 When tested in a human serum sample between 25 and 43 degrees C, the sens

230 Five sensor prototypes were tested in a human serum sample over one week and the maximum deviati

231 The power of COLMARm is demonstrated for a human serum sample uncovering the existence of 14 metabo

232 determination of complementary sequence in a human serum sample.

233 as robust and reliable to detect thrombin in human serum samples and its inhibition by hirudin.

234 obust immune evasion in nonhuman primate and human serum samples at dilution factors as high as 1:5,

235 Using human serum samples collected from 2009-10, 2010-11 and

236 at the system can be successfully applied to human serum samples for determining LDL concentrations.

237 r for JIA positive sample than for a pool of human serum samples from healthy individuals.

238 We evaluated our results on human serum samples from lymphoma patients and healthy c

239 e have identified a serum miRNA signature in human serum samples of mild to severe TBI, which can be

240 Human serum samples of MMTBI, severe TBI (STBI), orthope

241 Validation with human serum samples shows an excellent agreement when co

242 All mouse and human serum samples that were able to neutralize rMuVJL5

243 y, proposed biosensor was introduced to real human serum samples to determine HSP70 sensitively and a

244 In the current study we analyzed depleted human serum samples to evaluate experimental factors tha

245 presence of anti-Pneumocystis antibodies in human serum samples was detected by ELISA and Western bl

246 imultaneous detection of CA125 and CA15-3 in human serum samples was evaluated and the obtained resul

247 nosensor in common interferents and clinical human serum samples was investigated, showing comparable

248 Combining small RNA sequencing from 179 human serum samples with a neural network analysis produ

249 ion of OME in pharmaceutical formulation and human serum samples with mean recoveries of 100.97% and

250 ent glucose assays in standard solutions and human serum samples worked reproducibly with close to 10

251 h specificity and excellent recovery for the human serum samples, indicating its promising potential

252 In human serum samples, PYY concentrations were higher in s

253 nalysis of aqueous and organic extracts from human serum samples, spectral features were assigned to

254 i-interference capability in the presence of human serum samples.

255 oprobe as a function of QA concentrations in human serum samples.

256 avidin in undiluted, immunoglobulin-deprived human serum samples.

257 s Zaire ebolavirus) variant Makona in spiked human serum samples.

258 rocedure for the elimination of protein from human serum samples.

259 ermine the age range of the originator using human serum samples.

260 titatively analyzed with good reliability in human serum samples.

261 low detection limit (LOD) of 5.7 aM in real human serum samples.

262 iency in the capturing of AD biomarkers from human serum samples.

263 ng the glucose and cholesterol level of real human serum samples.

264 y for detection of HER2 in complex matrix of human serum samples.

265 Using MASP-3-depleted human serum, serum from 3MC patients, and Masp1/3(-/-) m

266 r QA detection in triple distilled water and human serum shows that it is unaffected by variation in

267 Human serum specimens from previously confirmed DENV inf

268 Mb rebinding was examined in Mb-free diluted human serum spiked with Mb as well as in plasma samples

269 nded for the detection of a model protein in human serum, that is, human immunoglobulin G, with the a

270 nveil the potential use of their quantity in human serum to mark the pathological elicitation of thes

271 EHDPHP were incubated separately with pooled human serum to measure the formation of hydrolysis produ

272 141-155) antibodies inhibited the binding of human serum to virions, which demonstrated that the VP2

273 Human serum transferrin (sTf) is a protein that mediates

274 luated toward the sensing of APAP and INH in human serum, urine, saliva, and tablet samples.

275 e determination of immunoglobulin E (IgE) in human serum using gold nanoclusters (AuNCs) as fluoresce

276 for the determination of (24R),25(OH)2D3 in human serum using isotope-dilution LC-MS/MS.

277 ection of prostate specific antigen (PSA) in human serum using silicon nanowire field effect transist

278 lebsiella pneumoniae, by B. bacteriovorus in human serum versus buffer.

279 enzo[a]pyrene, bisphenol A, and acrolein) in human serum via a competitive binding scheme.

280 matory biomarker C-reactive protein (CRP) in human serum via a miniature bead-based enzyme-linked imm

281 Limit of detection of 1pg/mL in human serum was achieved for both cTnI and cTnT.

282 Human serum was collected from adults and children follo

283 Neisseria meningitidis after incubation with human serum was completely C3-dependent, as detected by

284 s detection and quantification of HEV RNA in human serum was developed based on an adaptation of a pr

285 Polymorphism of haptoglobin in human serum was first discovered over 60 years ago.

286 e concentration range and as well as diluted human serum we further investigate the capacity of the p

287 ize the structures of N-glycans derived from human serum, we report a strategy that combines microchi

288 n precipitated samples from the same pool of human serum were comprehensively investigated using (1)H

289 ults from determination of HIV DNA target in human serum were obtained showing great potential of the

290 cribed, including a soluble form detected in human serum, which may have an immunosuppressive functio

291 erol efflux to acceptor (apo)lipoprotein and human serum, while loss of TSPO resulted in impaired cho

292 the range of 0.05 to 10 mug/mL in 25 muL of human serum with a wide range of anti-IgAP antibody leve

293 Further, we found that preincubation of human serum with F. alocis resulted in abolished bacteri

294 n gravimetrically prepared spiked samples of human serum with known (24R),25(OH)2D3 levels.

295 alysis of squamous cell carcinoma antigen in human serum with recoveries of 97.3%, 102.4% and 107.4%.

296 shed to determine neutralizing antibodies in human serum with reference to the FAMA test.

297 n, as demonstrated by the lack of binding in human serum with the C3-inhibitor compstatin Cp40, in C3

298 he selectivity of detecting cTnT and cTnI in human serum with wide dynamic range.

299 essfully implemented for detection of DNA in human serum without loss of signal.

300 's sensitivity to the bactericidal effect of human serum would further augment bacterial clearance.